proteomics

Byaibio

Proteomics is a multiomic technology that measures the protein complement of a sample, often via mass spectrometry-based proteomic profiling, to link genetic variation to gene regulation, cell-type vulnerability, and circuit dysfunction. It is used across disease areas including triple negative breast cancer, transthyretin amyloidosis, pulmonary arterial hypertension, psoriasis, cardiovascular disease, psychiatric disorders, tissue regeneration, and esophageal squamous cell carcinoma. In clinical and translational studies, it supports biomarker discovery, multidimensional molecular response tracking, and precision medicine, including analysis of dried blood spots and clinical samples. Recent literature highlights its role in identifying protein-based biomarkers, decoding post-translational modifications during healing, and integrating with artificial intelligence and other omics layers in multi-omics frameworks. Specific applications include proteome alterations in skin and plasma in psoriasis, protein associations with dendritic spine traits in dorsolateral prefrontal cortex, and biomarker refinement in breast cancer and cardiovascular risk prediction. Overall, proteomics functions as a high-throughput analytical layer for mechanistic discovery and clinical stratification, with growing use in integrative multi-omics studies.

Cancer

  • Proteomics was used to identify protein-based biomarkers for diagnosis, prognosis, treatment, and precision medicine in triple negative breast cancer. (PMID:41512917)
  • A 2026 review on multi-omics and artificial intelligence in breast cancer emphasized proteomics for diagnosis, prognostication, and precision oncology. (PMID:41616992)
  • Proteomics was one of the multi-omics layers synthesized for esophageal squamous cell carcinoma biomarker discovery. (PMID:42028731)
  • Proteomics was included among the multi-omics layers integrated with artificial intelligence for personalized breast cancer management. (PMID:41936855)
  • Proteomics was also discussed as part of multi-omics analysis in tumor immunotherapy. (PMID:41938619)

Cardiovascular and pulmonary disease

  • Proteomics contributed to novel models, biomarkers, and tools for cardiovascular risk prediction in a 2026 American Heart Association scientific statement. (PMID:41669831)
  • Multi-omics cardiovascular profiling included proteomics as an analytical layer for clinical translation. (PMID:42013055)
  • In a post-hoc analysis of the REHAB-PH trial, proteomics helped capture molecular responses and assess biomarker stability in pulmonary arterial hypertension. (PMID:41849831)
  • Proteomics was highlighted in precision medicine advances for steatotic liver disease, relevant to cardiometabolic risk contexts. (PMID:41912348)

Neurology and psychiatric disease

  • Proteomics was highlighted as a multiomic layer for decoding psychiatric disease mechanisms and linking genetic variation to gene regulation and circuit dysfunction. (PMID:41831411)
  • Multi-omics biomarkers in psychiatric disorders included proteomics for diagnosis and stratification. (PMID:41655615)
  • Mass spectrometry-based proteomic profiling of human dorsolateral prefrontal cortex identified proteins associated with dendritic spines. (PMID:41922169)
  • Proteomics was one of the multi-omics layers discussed in a review of psychiatric biomarker discovery. (PMID:41655615)

Amyloidosis and other clinical biomarker applications

  • Proteomics in clinical samples identified promising biomarkers in transthyretin amyloidosis. (PMID:41898867)
  • Dried blood spot proteomics profiling was evaluated for clinical trial biomarker discovery, supporting minimally invasive sampling. (PMID:41975197)
  • Proteomics was described as a high-throughput approach for biomarker discovery in clinical translational settings. (PMID:41898867)

Inflammation, regeneration, and systems biology

  • Proteomics decoded protein alterations and post-translational modifications during tissue regeneration and wound healing. (PMID:41848587)
  • In psoriasis, proteome alterations were described in both skin and plasma, showing disease-associated systemic and tissue-level changes. (PMID:41891974)
  • Integrative metabolomics and proteomics were used to synthesize molecular mechanisms underlying heat stress. (PMID:41605375)